Cyclic diarylheptanoids inhibit cell mediated low-density lipoprotein oxidation

Area of Science:

• Phytochemistry
• Pharmacology
• Biochemistry

Background:

• Oxidation of low-density lipoprotein (LDL) is a key factor in the development of atherosclerosis.
• Natural products are a rich source of compounds with potential therapeutic benefits.
• Alnus japonica fruits contain various bioactive compounds, including cyclic diarylheptanoids.

Purpose of the Study:

• To investigate the LDL oxidation inhibitory effects of garugamblin-3 and acerogenin L isolated from Alnus japonica.
• To compare the efficacy of these compounds with a known antioxidant, probucol.
• To evaluate the anti-atherogenesis potential of garugamblin-3 in vivo.

Main Methods:

• Isolation of cyclic diarylheptanoids (garugamblin-3 and acerogenin L) from Alnus japonica fruit methanol extract.
• Assessment of LDL oxidation inhibition using the thiobarbituric acid-reactive substance (TBARS) assay.
• Evaluation of cell-mediated LDL oxidation inhibition.
• In vivo anti-atherogenesis study using low-density lipoprotein receptor-deficient mice.

Main Results:

• Garugamblin-3 and acerogenin L demonstrated significant inhibition of LDL oxidation with IC(50) values of 2.9 microM and 1.7 microM, respectively.
• Both compounds were over 5 times more potent than probucol in inhibiting cell-mediated LDL oxidation at 10 microM.
• Garugamblin-3 did not exhibit anti-atherogenic effects in low-density lipoprotein receptor-deficient mice.

Conclusions:

• Garugamblin-3 and acerogenin L possess potent LDL oxidation inhibitory properties.
• These compounds represent potential natural antioxidants for cardiovascular health.
• Further investigation is required to elucidate the anti-atherogenesis mechanisms and therapeutic potential of these diarylheptanoids.